Trials / Completed
CompletedNCT04154800
A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants
A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BMS-986209 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the safety and tolerability of BMS-986209 in healthy participants. The first-in-human study is designed in 3 parts that vary based on duration and food effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986209 | Specified Dose on Specified Days |
| OTHER | BMS-986209 Placebo | Specified Dose on Specified Days |
| DRUG | Itraconazole | Specified Dose on Specified Days |
| DRUG | Diltiazem | Specified Dose on Specified Days |
Timeline
- Start date
- 2019-12-06
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
- First posted
- 2019-11-07
- Last updated
- 2022-01-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04154800. Inclusion in this directory is not an endorsement.